文献速递头颈与中枢神经肿瘤

Becotatug vedotin治疗复发/转移性鼻咽癌:多中心随机试验

Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial.
PubMed 文献 · Ann Oncol · 2026-06-17

Magic-M001研究纳入173例经≥2线系统治疗(含化疗和PD-1/PD-L1抑制剂)失败的复发/转移性鼻咽癌患者,1:1随机接受becotatug vedotin 2.3 mg/kg每3周或化疗(卡培他滨或多西他赛)。结果显示becotatug vedotin显著提高客观缓解率(30.2% vs 11.5%,P=0.003)并延长无进展生存期(5.82 vs 2.83个月,HR 0.63,95%CI 0.43-0.91,P=0.01),总生存期中期分析未达统计学显著差异(17.08 vs 11.99个月,HR 0.73,95%CI 0.48-1.12,P=0.15),安全性相当。

要点

  • becotatug vedotin较化疗显著提高ORR(30.2% vs 11.5%,P=0.003)和PFS(5.82 vs 2.83个月,HR 0.63,P=0.01)。
  • 中期OS分析未达显著差异(17.08 vs 11.99个月,HR 0.73,P=0.15),需更长随访。
  • 安全性两组相当,适用于经PD-1/PD-L1抑制剂和化疗失败的重度治疗患者。

核心结论

  • 在重度治疗且免疫治疗暴露的复发/转移性鼻咽癌患者中,becotatug vedotin较化疗显著改善ORR和PFS,毒性相当,OS结果鼓励但尚未成熟。

研究设计与样本

  • 多中心、开放标签、随机试验,纳入173例经≥2线系统治疗(含化疗和PD-1/PD-L1抑制剂)失败的复发/转移性鼻咽癌患者,1:1随机接受becotatug vedotin 2.3 mg/kg每3周(86例)或化疗(卡培他滨或多西他赛,87例)。

主要发现

  • 截至2024年6月30日,becotatug vedotin组ORR为30.2%,化疗组为11.5%(P=0.003)。
  • 中位随访7.39个月,becotatug vedotin组中位PFS为5.82个月,化疗组为2.83个月(HR 0.63,95%CI 0.43-0.91,log-rank P=0.01)。
  • 截至2024年12月30日,中位随访13.47个月,becotatug vedotin组中位OS为17.08个月,化疗组为11.99个月(HR 0.73,95%CI 0.48-1.12,log-rank P=0.15)。
  • 两组安全性特征相当。

关键数值与推荐

  • becotatug vedotin 2.3 mg/kg每3周静脉给药,对照化疗为卡培他滨或多西他赛。
  • 共同主要终点为独立评审委员会确认的ORR、PFS和OS。

临床怎么用

  • 对于经PD-1/PD-L1抑制剂和化疗失败的复发/转移性鼻咽癌患者,becotatug vedotin可显著改善ORR和PFS,且毒性可控,可作为新的治疗选择。

局限性

  • OS数据尚未成熟,需更长随访确认生存获益。
  • 研究为开放标签设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with recurrent/metastatic nasopharyngeal carcinoma (NPC) had limited treatment option and dismal prognosis after failure to programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors and chemotherapy. PATIENTS AND METHODS: This multicenter, open-label, randomized trial investigated the anti-epidermal growth factor receptor antibody-drug conjugate becotatug vedotin in patients with recurrent/metastatic NPC after failure to ≥2 lines of systemic therapies, including chemotherapy and PD-1/PD-L1 inhibitors. Eligible participants were randomly assigned 1:1 to receive becotatug vedotin 2.3 mg/kg every 3 weeks or chemotherapy (capecitabine or docetaxel). The coprimary endpoints were the independent review committee-confirmed objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). RESULTS: Between 6 April 2023 and 27 December 2023, a total of 173 patients were randomly assigned, with 86 assigned to becotatug vedotin and 87 to chemotherapy. As of 30 June 2024, the ORR was significantly higher with becotatug vedotin than with chemotherapy (30.2% versus 11.5%, P = 0.003). With a median follow-up of 7.39 months, becotatug vedotin was associated with a significantly reduced risk of disease progression or death compared with chemotherapy [median PFS, 5.82 versus 2.83 months; hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.43-0.91, log-rank P = 0.01]. As of 30 December 2024, the interim OS analysis showed a median OS of 17.08 months with becotatug vedotin and 11.99 months with chemotherapy (HR 0.73, 95% CI 0.48-1.12, log-rank P = 0.15), with a median follow-up of 13.47 months. The safety profiles were comparable between treatment groups. CONCLUSIONS: Among patients with heavily pretreated and immunotherapy-exposed recurrent or metastatic NPC, becotatug vedotin significantly improved ORR and PFS compared with chemotherapy, with comparable toxicity and encouraging but immature OS results.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Han F, Xiang YQ, Wang XH, et al. Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial. Ann Oncol. 2026. PMID: 42309209. doi:10.1016/j.annonc.2026.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。